Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 18, Issue 1, 2003, Pages 24-38

  Hahm, Ki Baik ^a   Kim, D H ^a   Lee, K M ^a   Lee, J S ^a   Surh, Y J ^a   Kim, Y B ^a   Yoo, B M ^a   Kim, J H ^a   Joo, H J ^a   Cho, Y K ^a   Nam, K T ^a   Cho, S W ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DNA; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PROTEIN P75; RANTES; REBAMIPIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ALANINE; ANTIULCER AGENT; DRUG DERIVATIVE; MATRIX METALLOPROTEINASE; PROTEIN; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATROPHIC GASTRITIS; ATTENUATION; BACTERIAL COLONIZATION; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHRONIC GASTRITIS; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; FEMALE; GASTRITIS; GENE EXPRESSION REGULATION; HELICOBACTER PYLORI; IMMUNOMODULATION; INFECTION RISK; LONG TERM EXPOSURE; METAPLASIA; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PATHOLOGICAL ANATOMY; PRECANCER; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH DISEASE; STOMACH MUCOSA; ANIMAL; ARTICLE; C57BL MOUSE; DRUG EFFECT; HELICOBACTER INFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROBIOLOGY; PATHOLOGY; PROTEIN BINDING; WESTERN BLOTTING;

ALANINE; ANIMALS; ANTI-ULCER AGENTS; APOPTOSIS; BLOTTING, WESTERN; CYTOKINES; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; NF-KAPPA B; PROTEIN BINDING; PROTEINS; QUINOLONES; RNA, MESSENGER;

EID: 0041847089     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.18.s1.3.x     Document Type: Conference Paper

References (48)

1. Israel DA, Peek RM. Pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther 2001; 15: 1271-90.
2. Mai UE, Perez-Perez GL, Allen JB, et al. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med 1992; 175: 517-25.
3. Yamaoka Y, Kita M, Kodama T, et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996; 110: 1744-52.
4. Go MF. What are the host factors that place an individual at risk for Helicobacter pylori-associated disease? Gastroenterology 1997; 113: 15-20.
5. Moss SF, Legon S, Davies J, Calam J. Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 1994; 35: 1567-70.
6. Yoshida N, Granger DN, Evans DJ, et al. Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology 1993; 105: 1431-40.
7. Bechi P, Balzi M, Becciolini A, et al. Helicobacter pylori and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis. Am J Gastroenterol 1996; 91: 271-6.
8. + strains and dissociation of gastric epithelial cell proliferation from apoptosis. J Natl Cancer Inst 1997; 89: 863-8.
9. Moss SF, Calam J, Agarwal B, et al. Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996; 38: 498-501.
10. Rautelin H, Blomberg B, Jarnerot G, et al. Nonopsonic activation of neutrophils and cytotoxin production by Helicobacter pylori: ulcerogenic markers. Scand J Gastroenterol 1994; 29: 128-32.
11. Zhang OB, Nakashabendi IM, Mokhashi MS, et al. Association of cytotoxin production and neutrophil activation by strains of Helicobacter pylori isolated from patients with peptic ulceration and chronic gastritis. Gut 1996; 38: 841-5.
12. Baik SC, Youn HS, Chung MH, et al. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res 1996; 56: 1279-82.
13. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998; 9: 5S-13S.
14. Yoshida N, Yoshikawa T, Iinuma S, et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41: 1139-44.
15. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12579, a novel antiulcer compound, in the rats. Eur J Pharmacol 1987; 142: 23-30.
16. Han BG, Kim HS, Rhee KH, Han Hs, Chung MH. Effects of rebamipide on gastric cell damage by Helicobacter pylori-stimulated human neutrophils. Pharmacol Res 1995; 32: 201-7.
17. Ernst P. The role of inflammation in the pathogenesis of gasrtric cancer. Aliment Pharmacol Ther 1999; 13: 13-8.
18. Hahm KB, Lee KJ, Choi SY, et al. Possibility of chemoprevention by the eradication of Helicobacter pylori: oxidative DNA damage and apoptosis in H. pylori infection. Am J Gastroenterol 1997; 92: 1853-57.
19. Sugiyama A, Maruta F, Ikeno T, et al. Helicobacter pylori infection N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian Gerbils. Cancer Res 1998; 58: 2067-9.
20. Moss SF. Cellular markers in the gastric precancerous process. Aliment Pharmacol Ther 1998; 12: 91-109.
21. Kishimoto S. Therapeutic effects of oral rebamipide and in combination with cimetidine on experimental gastritis in rats. Res Commun Chem Pathol Pharmacol 1992; 78: 259-77.
22. Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel anti-ulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994; 35: 1375-8.
23. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 1998; 43: 160S-166S.
24. Iinuma S, Naito Y, Yoshikawa T, et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci 1998; 43: 35S-39S.
25. Ernst PB, Crowe SE, Reyes VE. How does Helicobacter pylori cause mucosal damage? The inflammatory response. Gastroenterology 1997; 113: S35-S42.
26. Rieder G, Hatz RA, Moran AP, Walz A, Stoke M, Enders G. Role of adherence in interleukin-8 induction in Helicobacter pylori-associated gastritis. Infection Immunity 1997; 65: 3622-30.
27. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between cytokines and Helicobacter pylori in gastric cancer. Helicobacter 2001; 6: 116-24.
28. Crabtree JE, Shallcross TM, Heatley RV, et al. Mucosal tumor necrosis factor α and interleukin-6 in patients with Helicobacter pylori-associated gastritis. Gut 1991; 32: 1473-7.
29. Bamford KB, Fan X, Crowe SE, et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998; 114: 482-92.
30. Sakagami T, Dixon M, O'Rourke J, et al. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 1996; 39: 639-48.
31. Mohammadi M, Czinn S, Redline R, et al. Murine CD4 T-cell response to Helicobacter infection: Th1 cells enhance gastritis and Th2 cells reduce bacterial load. Gastroenterology 1997; 113: 1848-57.
32. Mori N, Wada A, Hirayama T, Parks TP, Stratowa C, Yamamoto N. Activation of intercellular adhesion molecule 1 expression by Helicobacter pylori is regulated by NF-κB in gastric epithelial cancer cells. Infection Immunity 2000; 68: 1806-14.
33. Keates S, Hitti YS, Upton M, et al. Helicobacter pylori infection activates NF-κB in gastric epithelial cells. Gastroenterology 1997; 113: 1099-109.
34. Sharma SA, Tummuru MK, Blasér MJ, et al. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-κB in gastric epithelial cells. J Immunol 1998; 160: 2401-7.
35. Mckay LI, Cidlowski JA. Molecular control of immune/inflammatory response; Interactions between nuclear factor-κB and steroid receptor-signaling pathway. Endocrine Rev 1999; 20: 435-59.
36. Schreck R, Albermann K, Baeuelre PA. Nuclear factor kappa B. an oxidative stress response transcription factor of eukaryotic cells. Free Rad Res Commun 1992; 17: 221-7.
37. Konturek PC, Konturek SJ, Pierzxhalski P, et al. Cancerogenesis in Helicobacter pylori infected stomach - role of growth factors, apoptosis, and cyclooxygenases. Med Sci Monit 2001; 7: 1092-107.
38. Asaka M, Kudo M, Kato M, Sugiyama T, Takeda H. Long-term Helicobacter pylori infection - from gastritis to gastric cancer. Aliment Pharmacol Ther 1998; 12: 9-15.
39. Jones NL, Day AS. Jennings HA. Sherman PM. Helicobacter pylori induces gastric epithelial cell apoptosis in association with increased Fas receptor expression. Infection Immunity 1999; 67: 4237-42.
40. + Helicobacter pylori strains. Laboratory Invest 1995; 73: 760-70.
41. Wang J, Fan X, Lindholm C, et al. Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through Fas/Fas ligand interactions. Infect Immun 2000; 68: 4303-11.
42. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 16: 3-15.
43. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
44. Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997; 113: S56-S60.
45. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19: 37-43.
46. Momand J. Zambetti GP. MDM-2. 'big brother' of p53. J Cell Biochem 1997; 64: 343-52.
47. Mori M, Honda M, Shibuta K, et al. Expression of ornithine decarboxylase mRNA in gastric carcinoma. Cancer 1996; 77: 1634-8.
48. Lefebvre O, Chenard MP, Masson R, et al. Gastric mucosal abnormoalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-62.